218 related articles for article (PubMed ID: 29915380)
1. Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Waggoner D; Wain KE; Dubuc AM; Conlin L; Hickey SE; Lamb AN; Martin CL; Morton CC; Rasmussen K; Schuette JL; Schwartz S; Miller DT;
Genet Med; 2018 Oct; 20(10):1105-1113. PubMed ID: 29915380
[TBL] [Abstract][Full Text] [Related]
2. A cohort study of neurodevelopmental disorders and/or congenital anomalies using high resolution chromosomal microarrays in southern Brazil highlighting the significance of ASD.
Chaves TF; Ocampos M; Barbato IT; de Camargo Pinto LL; de Luca GR; Barbato Filho JH; Bernardi P; Costa Netto Muniz Y; Francesca Maris A
Sci Rep; 2024 Feb; 14(1):3762. PubMed ID: 38355898
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal Microarray With Clinical Diagnostic Utility in Children With Developmental Delay or Intellectual Disability.
Lee JS; Hwang H; Kim SY; Kim KJ; Choi JS; Woo MJ; Choi YM; Jun JK; Lim BC; Chae JH
Ann Lab Med; 2018 Sep; 38(5):473-480. PubMed ID: 29797819
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal Aberrations in Pediatric Patients with Developmental Delay/Intellectual Disability: A Single-Center Clinical Investigation.
Hu T; Zhang Z; Wang J; Li Q; Zhu H; Lai Y; Wang H; Liu S
Biomed Res Int; 2019; 2019():9352581. PubMed ID: 31781653
[TBL] [Abstract][Full Text] [Related]
5. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.
Miller DT; Adam MP; Aradhya S; Biesecker LG; Brothman AR; Carter NP; Church DM; Crolla JA; Eichler EE; Epstein CJ; Faucett WA; Feuk L; Friedman JM; Hamosh A; Jackson L; Kaminsky EB; Kok K; Krantz ID; Kuhn RM; Lee C; Ostell JM; Rosenberg C; Scherer SW; Spinner NB; Stavropoulos DJ; Tepperberg JH; Thorland EC; Vermeesch JR; Waggoner DJ; Watson MS; Martin CL; Ledbetter DH
Am J Hum Genet; 2010 May; 86(5):749-64. PubMed ID: 20466091
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Karyotyping, Chromosomal Microarray Analysis, and Targeted Next-Generation Sequencing of Patients with Unexplained Global Developmental Delay or Intellectual Disability.
Li Y; Anderson LA; Ginns EI; Devlin JJ
Mol Diagn Ther; 2018 Feb; 22(1):129-138. PubMed ID: 29209992
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal microarray testing influences medical management.
Coulter ME; Miller DT; Harris DJ; Hawley P; Picker J; Roberts AE; Sobeih MM; Irons M
Genet Med; 2011 Sep; 13(9):770-6. PubMed ID: 21716121
[TBL] [Abstract][Full Text] [Related]
8. Clinical Performance of an Ultrahigh Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders.
Ho KS; Twede H; Vanzo R; Harward E; Hensel CH; Martin MM; Page S; Peiffer A; Mowery-Rushton P; Serrano M; Wassman ER
Biomed Res Int; 2016; 2016():3284534. PubMed ID: 27975050
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal Microarray Analysis as a First-Tier Clinical Diagnostic Test in Patients With Developmental Delay/Intellectual Disability, Autism Spectrum Disorders, and Multiple Congenital Anomalies: A Prospective Multicenter Study in Korea.
Jang W; Kim Y; Han E; Park J; Chae H; Kwon A; Choi H; Kim J; Son JO; Lee SJ; Hong BY; Jang DH; Han JY; Lee JH; Kim SY; Lee IG; Sung IK; Moon Y; Kim M; Park JH
Ann Lab Med; 2019 May; 39(3):299-310. PubMed ID: 30623622
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features.
Battaglia A; Doccini V; Bernardini L; Novelli A; Loddo S; Capalbo A; Filippi T; Carey JC
Eur J Paediatr Neurol; 2013 Nov; 17(6):589-99. PubMed ID: 23711909
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility and cost-effectiveness analysis of chromosome testing concomitant with chromosomal microarray of patients with constitutional disorders in a U.S. academic medical center.
Su M; Page S; Haag M; Swisshelm K; Hennerich D; Graw S; LeRoux J; Brzeskiewicz P; Svihovec S; Bao L
J Genet Couns; 2022 Apr; 31(2):364-374. PubMed ID: 34397147
[TBL] [Abstract][Full Text] [Related]
12. Can clinical characteristics be criteria to perform chromosomal microarray analysis in children and adolescents with autism spectrum disorders?
Sys M; van den Bogaert A; Roosens B; Lampo A; Jansen A; Wouters S; Keymolen K
Minerva Pediatr; 2018 Jun; 70(3):225-232. PubMed ID: 27607483
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal Microarray Testing for Children With Unexplained Neurodevelopmental Disorders.
Martin CL; Ledbetter DH
JAMA; 2017 Jun; 317(24):2545-2546. PubMed ID: 28654998
[No Abstract] [Full Text] [Related]
14. Chromosomal microarray analyses from 5778 patients with neurodevelopmental disorders and congenital anomalies in Brazil.
Krepischi ACV; Villela D; da Costa SS; Mazzonetto PC; Schauren J; Migliavacca MP; Milanezi F; Santos JG; Guida G; Guarischi-Sousa R; Campana G; Kok F; Schlesinger D; Kitajima JP; Campagnari F; Bertola DR; Vianna-Morgante AM; Pearson PL; Rosenberg C
Sci Rep; 2022 Sep; 12(1):15184. PubMed ID: 36071085
[TBL] [Abstract][Full Text] [Related]
15. Clinical Application of Chromosome Microarray Analysis in Han Chinese Children with Neurodevelopmental Disorders.
Xu M; Ji Y; Zhang T; Jiang X; Fan Y; Geng J; Li F
Neurosci Bull; 2018 Dec; 34(6):981-991. PubMed ID: 29948840
[TBL] [Abstract][Full Text] [Related]
16. Interpretation and reporting of large regions of homozygosity and suspected consanguinity/uniparental disomy, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG).
Gonzales PR; Andersen EF; Brown TR; Horner VL; Horwitz J; Rehder CW; Rudy NL; Robin NH; Thorland EC; On Behalf Of The Acmg Laboratory Quality Assurance Committee
Genet Med; 2022 Feb; 24(2):255-261. PubMed ID: 34906464
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders.
Srivastava S; Love-Nichols JA; Dies KA; Ledbetter DH; Martin CL; Chung WK; Firth HV; Frazier T; Hansen RL; Prock L; Brunner H; Hoang N; Scherer SW; Sahin M; Miller DT;
Genet Med; 2019 Nov; 21(11):2413-2421. PubMed ID: 31182824
[TBL] [Abstract][Full Text] [Related]
18. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013.
South ST; Lee C; Lamb AN; Higgins AW; Kearney HM;
Genet Med; 2013 Nov; 15(11):901-9. PubMed ID: 24071793
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal microarray detects genetic risks of neurodevelopmental disorders in newborns with congenital heart disease.
Gill K; Sasaki J; Jayakar P; Sosa L; Welch E
Cardiol Young; 2021 Aug; 31(8):1275-1282. PubMed ID: 33536103
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal Microarray Analysis of Consecutive Individuals with Autism Spectrum Disorders Using an Ultra-High Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders.
Ho KS; Wassman ER; Baxter AL; Hensel CH; Martin MM; Prasad A; Twede H; Vanzo RJ; Butler MG
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
